Background. Translocation of microbial products from the damaged gut causes increased immune activation in human immunodeficiency virus (HIV). Proton pump inhibitors (PPIs) predispose to bacterial overgrowth in the gut. We hypothesized that longterm use of PPIs is associated with greater microbial translocation and immune activation in HIV.
Methods. HIV-infected persons on suppressive antiretroviral therapy (ART), including those receiving long-term PPIs (PPI + group) or not (PPI − group), were enrolled. We determined CD38 + HLA-DR + CD8 + (activated) T-cell frequency, and plasma levels of lipopolysaccharide (LPS), LPS binding protein (LBP), soluble CD14 (sCD14), and intestinal fatty acid binding protein (I-FABP).
Results. We recruited 77 HIV-infected participants (37 PPI + and 40 PPI − ) and 20 HIV-uninfected volunteers. PPI + subjects were older and more likely to have hypertension and receive statins than PPI − . Nadir and enrollment CD4 counts, activated T-cells, and time on ART were similar in both groups. PPI + group had higher sCD14 (2.15 vs. 1.50 mcg/mL, P < .01), and LBP (21.78 vs. 18 .28 mcg/mL, P = .02) but lower I-FABP levels (608.5 vs. 2281.7 pg/mL, P = .05) than PPI -. In multivariate analysis, sCD14 levels remained associated with PPIs. In the year prior to enrollment, PPI + group lost more CD4 cells than PPI − (−18 vs. 54 cells/mm 3 , P = .03). HIV-infected subjects had higher immune activation and microbial translocation biomarkers than uninfected volunteers.
Conclusion. In HIV, long-term use of PPIs was associated with increased microbial translocation, innate immune activation, and reduced immune reconstitution. Further studies are needed to evaluate the clinical implications of our findings. In the meantime, cautious use of PPIs is advised.
Keywords. HIV; proton pump inhibitors; immune activation.
Human immunodeficiency virus (HIV) infection is character-
ized by qualitative and quantitative defects of the immune system. An exaggerated systemic immune activation, measured as higher levels of activated CD8 + T cells (CD8   +   CD38   +   HLA-DR   +   ) , is one of the best predictors of progression to AIDS [1, 2] .
Gut microbial product translocation from an impaired gastrointestinal mucosal barrier is a main driver of systemic immune activation and progression of HIV disease [3] . Indeed, circulating plasma levels of lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, and soluble CD14 (sCD14), a marker of LPS-induced monocyte/macrophage activation, are significantly higher in chronically HIV-infected individuals compared to healthy participants [3] . Furthermore, antiretroviral therapy (ART) decreases markers of immune activation and microbial product translocation; however, these markers do not return to levels comparable to those of uninfected persons. Even in the setting of virologic suppression (with or without ART), low levels of gut microbial product translocation and immune activation continue to occur, although at lower level, and are associated with lower CD4 + T-cell counts [4] .
Treatment with proton pump inhibitors (PPIs) reduces the production of gastric acid [5] . Some studies have demonstrated that gastric acid reducers, particularly PPIs, predispose to microbial overgrowth in the upper gastrointestinal tract and may alter the gut microbiome; this may further exacerbate the dysbiosis in HIV-infected persons [6] [7] [8] . Observational studies in the general population have raised a number of safety concerns among users of PPIs. For instance, PPIs have been associated with an increased risk of gastrointestinal infections such as those due to Salmonella sp, Cholera sp, Campylobacter sp [5] , and Clostridium difficile [9, 10] , and extraintestinal infections including hospital-and community-acquired pneumonia [11, 12] , and spontaneous bacterial peritonitis [13] .
In this exploratory study, we hypothesize that among HIVinfected patients who have experienced ART-induced virologic suppression, the long-term use of PPIs is associated with increased microbial overgrowth and immune activation and consequently, impaired immunologic recovery.
METHODS
The study population consisted of HIV-1-infected persons who were receiving care at the HIV Clinic of the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) between October 2011 and December 2013. The study protocol was approved by the Institutional Review Board for human studies at Baylor College of Medicine and the Research and Development committee at the MEDVAMC. Written informed consent was provided by all study participants.
Study Participants
We included adults (age 18 or older) with confirmed HIV-1 (enzyme-linked immunosorbent assay [ELISA] test confirmed by Western blot) who have been receiving ART for at least 18 months with ART-induced virologic suppression for at least 12 months prior to enrollment. Study participants included those who were on long-term PPI use, defined as filling at least six 30-day supplies in the 12-month period prior to (PPI + group, 37 subjects), and those who were not taken any gastric acid reducers, including PPIs, H-2 blockers or antacids (PPI -group, 40 subjects). We excluded people who had liver cirrhosis, inflammatory bowel disease, cancer of the gastrointestinal tract, small bowel or colon surgery during the previous 2 years, or who were taking unboosted atazanavir or nelfinavir (due to potential interactions with PPIs). We also excluded those patients who have received any antibiotic in the last 4 weeks prior to study enrollment other than routine prophylaxis for Pneumocystis jiroveci pneumonia or Mycobacterium avium complex.
We also recruited 20 healthy (HIV-uninfected) volunteers for assay comparison purposes.
Procedures
HIV-infected participants, including those on long-term PPIs and those who had not taken any gastric acid reducers, were explained study details and asked to participate.
After subjects signed informed consent, we performed a review of medical records to collect demographic information, date of HIV-1 diagnosis, history of AIDS-defining illness, baseline comorbidities, chronic hepatitis B, chronic C infection regardless of previous treatment, ART start date, type of ART, nadir CD4 + T-cell count, detailed history of intake of PPIs, any other acid suppressing agent (H2 receptor blocker and antacids), current use of statins, nadir CD4 + T-cell count, and CD4 + T-cell counts at enrollment and 1 year prior to enrollment. In sum, 20 mL of blood was drawn from every participant for measurement of CD38 [16] .
Statistical Analysis
We used conventional measurements of central location and dispersion to describe the data. The primary endpoint of the study was the evaluation of microbial translocation and immune activation markers in HIV-infected PPI + and PPI − subjects. A sample size was calculated based on a 2-tailed, 2-sample Student's t test. Mean of plasma sCD14 in HIV-infected PPI − subjects was assumed to be 2.33 mcg/mL, and standard deviation for both HIV-infected groups was 0.5, on the basis of previous data [15, 17] . The power was set at 80%, the type 1 error at 0.05, and the hypothesized mean difference at 0.33. With these parameters, the required sample size in each group was 37 subjects. Demographic and clinical characteristics as well as levels of microbial translocation, immune activation, and gut epithelial biomarkers (log 10 -transformed) of HIV-infected PPI + and PPI − subjects were compared and tested for significant differences using a Student t test for continuous variables and χ 2 test or Fisher's exact test for categorical variables. Variables that showed a P-value < .1 in the univariate analysis were considered in the elaboration of a multivariate logistic regression model.
HIV-Infected and Healthy HIV-Uninfected Groups Were Also Compared
We also analyzed the data by performing multiple linear regression analyses. For these multivariate models, we used clinical, and laboratory characteristics of study participants are presented in Table 1 . HIV-infected participants on long-term PPIs were older (59.6 and 54.3 years old, P = .02) and more likely to have hypertension (76% and 50%, respectively, P = .02) and to receive statins (54% vs. 25%; P = .01) than patients who had not taken gastric acid reducers. Nadir and enrollment CD4 + T-cell counts as well as length of time receiving ART were similar between HIV-infected groups (Table 1) .
HIV-infected participants on PPIs had significantly higher plasma levels of sCD14 (2.15 vs. 1.50 mcg/mL, P < .01) and LBP (21.78 vs. 18.28 mcg/mL, P = .02) but lower I-FABP (608.5 vs. 2281.7 pg/mL, P = .05) when compared with patients who had not taken gastric acid reducers. Participants taking PPIs had higher levels of LPS, but the difference did not reach statistical significance (25.67 vs. 20.67 pg/mL, P = .06) (Figure 1 Figure 1) . In a multivariate logistic regression analysis, long-term use of PPIs remained significantly associated with higher levels of sCD14 (P < .01) after adjustment for age, hypertension, and use of statins. Levels of sCD14 and age were treated as continuous variables in this model.
In a multiple linear regression analysis using sCD14 level as the dependent variable, long-term use of PPIs was the only variable that remained significantly (P < .01) associated with higher sCD14 levels in a model that included age, race, chronic kidney disease, and coronary artery disease.
Among HIV-infected participants on PPIs, the median CD4 + T-cell count at the time that PPIs were first prescribed was 554 (interquartiles 25th-75th: 388-751) cells/mm 3 . The median 
DISCUSSION
Our findings revealed that the long-term use of PPIs in HIVinfected patients is associated with significantly increased innate immune activation, as demonstrated by higher plasma levels of sCD14, compared with those in patients who had not received any gastric acid reducers. The increase in immune activation was driven by enhanced translocation of microbial products as suggested by the higher plasma levels of LBP and LPS. HIV infection has been associated with significant immunological and structural damage of the intestinal mucosa. The gastrointestinal tracts of HIV-infected patients experience significant early loss of CD4 + T cells, epithelial cell degeneration, enterocyte apoptosis, crypt hyperplasia, and decreased expression of tight junction proteins [18] [19] [20] . This leads to increased mucosal permeability. Dysbiosis or alterations in the composition of the gut microflora exacerbate these changes. Although evidence is somewhat conflicting, microbiota of HIV-infected participants showed a relative increase of proteobacteria, and a decrease of bacteriodes. Gut epithelial barrier dysfunction, and innate immune activation, measured by sCD14 levels, predict mortality in treated HIV infection [15, 21] . Our study suggests that long-term use of PPIs in HIV infection increases translocation of microbial products and innate immune activation. The lower levels of I-FABP in the PPI group may indicate slower intestinal epithelial cell turnover and repair. Indeed, I-FABP levels increase, intestinal breaches reverse, and sCD14 levels decrease, after starting ART, indicating that lower I-FABP levels could be associated with less intestinal repair [22] . By predisposing to microbial overgrowth, PPIs might further exacerbate dysbiosis in HIV infection. Whether this worsening microbial translocation and immune activation in the setting of PPI use translates into an increased mortality will need to be elucidated in future studies.
In a hypothesis generating analysis, HIV-infected participants on long-term PPIs did not gain CD4 + T cells during the year preceding enrollment, whereas HIV-infected PPI -participants had a significant increase in CD4 + T-cells. We suspect that the suppressed CD4 + T-cell count gain was probably the result of progressively increased innate immune activation among these patients. Lederman et al [23] have shown that higher levels of innate and adaptive immune activation markers are associated with immunologic failure in people with treated HIV infection. Similarly, in a prospective cohort study in Uganda, Hunt et al demonstrated that higher levels of immune activation and lower CD4 + T-cell count recovery were associated with increased mortality [24] . Because no correlation between the number of months on PPIs and CD4 + T-cell count changes was observed, it seems that there was not an accumulative effect of PPI use. However, these patients had been heavily exposed to PPI (Interquartile range (IQR) prior time on PPI 1.8-6.5 years). Perhaps if patients with shorter duration on PPI use had been included this accumulative effect would have been observed. Our study has some limitations. We used a convenience sample consisting of consecutive HIV-infected patients regularly seen in an HIV clinic. This was due to the need for accurate data documentation to meet strict definition of long-term use of PPIs. As with any observational studies, unmeasured confounders might have affected some of our results. However, we did perform exhaustive statistical analyses to control for potential measured confounders. Our study population mostly consisted of middle-aged adult male veterans so our results may not be extrapolated to other populations. Finally, adherence to antiretroviral regimen was not formally recorded. However, all study participants had undetectable viral loads at study entry, and for at least 1 year, minimizing the effect of nonadherence in the results.
In summary, our study demonstrated that among HIVinfected patients, the long-term use of PPIs was associated with greater microbial translocation, increased innate immune activation, and probably lower ART-driven immunologic recovery. Further studies are needed to evaluate the clinical implications of our findings. In the meantime, cautious use of PPIs is advised in this population. 
